Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Current Leases (2019 - 2025)

aTYR PHARMA's Current Leases history spans 7 years, with the latest figure at $630000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 16.45% year-over-year to $630000.0; the TTM value through Dec 2025 reached $630000.0, up 16.45%, while the annual FY2025 figure was $630000.0, 16.45% up from the prior year.
  • Current Leases reached $630000.0 in Q4 2025 per ATYR's latest filing, down from $799000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.0 million in Q1 2022 to a low of $70000.0 in Q2 2022.
  • Average Current Leases over 5 years is $651315.8, with a median of $630000.0 recorded in 2022.
  • Peak YoY movement for Current Leases: tumbled 92.38% in 2022, then skyrocketed 787.14% in 2023.
  • A 5-year view of Current Leases shows it stood at $949000.0 in 2021, then plummeted by 33.61% to $630000.0 in 2022, then skyrocketed by 31.9% to $831000.0 in 2023, then plummeted by 34.9% to $541000.0 in 2024, then rose by 16.45% to $630000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Current Leases are $630000.0 (Q4 2025), $799000.0 (Q3 2025), and $562000.0 (Q2 2025).